1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Chronic Myeloid Leukemia (CML) Treatment Market
2.3. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment, 2025 (US$ Million)
2.4. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Geography, 2025 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2025
3. Chronic Myeloid Leukemia (CML) Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Chronic Myeloid Leukemia (CML) Treatment Market Vendors
3.2. Strategies Adopted by Chronic Myeloid Leukemia (CML) Treatment Market Vendors
4. Chronic Myeloid Leukemia (CML) Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Chronic Myeloid Leukemia (CML) Treatment Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape
5. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Targeted Therapy
5.3.1.1. Imatinib
5.3.1.2. Dasatinib
5.3.1.3. Nilotinib
5.3.1.4. Bosutinib
5.3.1.5. Ponatinib
5.3.2. Chemotherapy
5.3.3. Radiation Therapy
5.3.4. Splenectomy
5.3.5. Stem Cell Transplant
6. North America Chronic Myeloid Leukemia (CML) Treatment Market, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
6.3. Chronic Myeloid Leukemia (CML) Treatment Market: By Region, 2024-2034, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
7. UK and European Union Chronic Myeloid Leukemia (CML) Treatment Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
7.3. Chronic Myeloid Leukemia (CML) Treatment Market: By Region, 2024-2034, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
7.3.1.5. France
7.3.1.5.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
8. Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
8.3. Chronic Myeloid Leukemia (CML) Treatment Market: By Region, 2024-2034, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
8.3.1.3. India
8.3.1.3.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
9. Latin America Chronic Myeloid Leukemia (CML) Treatment Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
9.3. Chronic Myeloid Leukemia (CML) Treatment Market: By Region, 2024-2034, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
10. Middle East and Africa Chronic Myeloid Leukemia (CML) Treatment Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
10.3. Chronic Myeloid Leukemia (CML) Treatment Market: By Region, 2024-2034, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2024-2034, USD (Million)
11. Company Profile
11.1. Novartis AG (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
11.2. Bristol-Myers Squibb
11.3. Teva Pharmaceuticals Industries Ltd.
11.4. ARIAD Pharmaceuticals, Inc.
11.5. Pfizer, Inc.
11.6. Hospira, Inc.
11.7. Prism Pharmaceuticals
11.8. Incyte Corporation
11.9. Bio-Path Holdings
11.10. Stragen Pharma SA
11.11. Otsuka Pharmaceutical Co., Ltd.
